constitutively; however, the function of these receptors has not been fully delineated. W e discovered that IL-PRB directs two biologic activities in human monocytes, the release of granulocyte-macrophage colony-stimulating factor (GM-CSF) and increased susceptibility to lysis by lymphokineactivated killer cells (LAK) cells. Human monocytes were purified from peripheral blood mononuclear cells by plastic adherence and anti-CD2 plus complement lysis. By a 5-hour "Cr-release assay, monocytes cultured in IL-2 were found to gain increasing susceptibility to LAK cells with time and this effect was dose dependent. Maximal susceptibility was obtained with a 4-day culture in 1,000 U/ HE ACTIONS OF interleukin-2 (IL-2) are extensive and
T influence many cells of the hematopoietic system.
Among the first functions of IL-2 to be discovered were Tlymphocyte proliferation, induction of B-cell differentiation to secrete Ig, and activation of natural killer (NK) cells against tumor targets, which all involved cells of the lymphocytic cell lineage.'-4 A dose-dependent increase in circulating lymphokine-activated killer (LAK) cells with potent in vitro antitumor effects has been observed in cancer patients receiving recombinant human IL-2 (rhIL-2) infusion^.^ In patients with renal cell carcinoma and metastatic melanoma treated with rhIL-2 with or without an infusion of autologous in vitro activated LAK cells, complete and durable responses have been achieved in a small fraction of patients.6-8 Phase I1 clinical trials are being conducted with apparent activity in patients with neuroblastoma, non-Hodgkin's lymphoma, Hodgkin's lymphoma, ovarian carcinoma, and lymphoid malignancies for consolidation after bone marrow transplantatiom9-I3 Alternatively, rhIL-2 has been used clinically for the in vitro expansion of tumor-infiltrating lymphocytes (TIL), which consists of expanded populations of lymphocytes generated from the patient's tumor after surgical ex~ision.'~*'~ This type of immunotherapy has produced clinical responses, but is plagued with technical difficulties in the generation of sufficient numbers of TIL.
The limiting factor of IL-2 administration to cancer patients is the occurrence of severe adverse effects when ad- ministered in doses necessary to achieve a clinical response. Administration of high-dose rhIL-2 induces hypotension, renal dysfunction, hepatic dysfunction, chills and fever, fluid retention with vascular leak syndrome, and cardiotoxicity. '6 The mechanism of this toxicity has not been fully delineated, but may involve nonspecific lysis of normal, nonmalignant targets by activated LAK ~ells.~'~'* Tumor necrosis factor a (TNFa) has been shown to be released in response to IL-2, which could also contribute to the toxicity." IL-2-treated human lymphocytes have been shown to rapidly bind endothelial cells and cause their lysis." Cultured human monocytes that express macrophage differentiation antigens show susceptibility to lysis by LAK cells and this susceptibility can be modulated by cocultivation of the monocytes with certain cytokines. Granulocyte-macrophage colony-stimulating factor (GM-CSF) enhances susceptibility of human monocytes to LAK lysis, whereas interferon y (IFNy) reduces lysis.zo,21 Monocytes and tissue macrophages serve a very important purpose in antigen presentation, phagocytosis, and cytotoxicity of tumor cells. The lysis of monocytes by LAK cells may alter tumoricidal function and enhance clinical toxicity of rhIL-2. Therefore, a better understanding of IL-2 and its impact on monocytes would be desirable.
The cellular receptor responsible for mediating IL-2 effects on lymphocytes has been well de~cribed.~~.'~ The IL-2R consists of at least three polypeptide subunits and exists in three distinct forms with different binding affinities. One of the IL-2R constituents is a 55-Kd protein, IL-2Ra (CD25), which is recognized by the anti-Tac antibody and binds IL-2 with the lowest affinity of the three receptor species. 22 There is a 70-to 75-Kd protein designated IL-2RP that binds IL-2 with intermediate affinity and is responsible for signal transduction through a long cytoplasmic domain.23. 26 The third component of the IL-2R, the IL-2Ry chain, has only been recently described. This molecule immunoprecipitated with approximately 10% to 14% of NK cell IL-2RP chains. The function of this third component has not been fully defined, but appears to be involved in IL-2 signal t r a n s d~c t i o n .~~
The third form of IL-2R exists when both IL-2Ra and IL-2RP are both expressed on the cell surface as a heterodimer and form a high-affinity receptor.24 Primarily, this form of the receptor is expressed during conditions of lymphocytic activation.
GM-CSF RELEASE AND LAK SUSCEPTIBILITY IN MONOCYTES 3131
Recently, IL-2Rs have also been detected on nonlymphoid cell^.^^"^ Monocytes exhibit enhanced tumoricidal function when exposed to IL-2 and express IL-2RP con~titutively.~~ IL-2Ra is differentially expressed when exposed to some cytokines or mitogens, but not in response to IL-Z.29 Little is known about the function of IL-2RP on monocytes. The purpose of this study is to determine the relationship between IL-2 treatment of monocytes and their susceptibility to LAK cell lysis and the contribution of IG2RP to this phenomenon.
In this report, we show enhanced lysis of monocytes by LAK cells after treatment of the monocytes with IL-2 in a dose-dependent manner, as determined by a 5-hour 51Cr-release assay. We also found that IL-2 induces monocytes to release GM-CSF with coincident dose and kinetics to IL-2 exposure. Also, we discovered that the susceptibility of monocytes to lysis by LAK cells could be mitigated by pretreatment with antibodies to both IL-2RP and GM-CSF. Our results, taken together, suggest that IL-ZRP plays a role in the homeostasis of activated human monocytes and that this function is mediated by the cellular release of GM-CSF, which then induces the sensitization of monocytes to LAK lysis. Preparation of human peripheral blood mononuclear cells (PBMC). Leukocyte buffy coats were obtained from volunteers at the Southwest Florida Blood Bank (Tampa, FL). The blood was diluted 1:2 with phosphate-buffered saline (PBS; M. A. Biologics, Walkersville, MD) and layered on 12 mL of Ficoll-Hypaque (Pharmacia, Piscataway, NJ) and centrifuged at 400g for 20 minutes at room temperature, as previously described." The PBMC were collected and washed twice with PBS. The washed PBMC were placed in complete medium containing RPMI 1640 with 5% heat-inactivated human AB serum (Flow, McLean, VA), 2 mmol/L L-glutamine, 100 U/mL of penicillin, 100 pg/mL of streptomycin, 5 mmol/L HEPES, and 5 X IO-' mol/L 2-mercaptoethanol (GIBCO, Grand Island, NY).
MATERIALS AND METHODS

Antibodies
Monocytes were separated by plastic adherence for 60 minutes at 37°C on gelatin coated 25-cm2 tissue culture flasks (Costar, Cambridge, MA). Nonadherent cells (NAC) were removed by vigorous washing with warm RPMI 1640.
Purification of monocytes. In isolating adherent monocytes, up to 5% T cells and large granular lymphocytes (LGL) can contaminate adherent cells recovered from the plastic surface. Therefore, further purification was accomplished by anti-CD2 plus complement-mediated lysis of contaminating T and NK cells. Anti-CD2 MoAb (40 pg) was incubated with adherent monocytes after the removal of NAC. Low-Tox-H rabbit complement (Cedar Lane Laboratories, Hornby, Ontario, Canada) was diluted 1:8 with RPMI 1640, filtered, and applied to the antibody-treated monocytes for 45 minutes at 37°C. This procedure was repeated twice before culturing the purified monocytes in complete medium with or without IL-2 at 37°C for 1 to 4 days. In specified experiments, either 10 pg of anti-IL-2Rp mouseantihuman MoAb or polyclonal rabbit antihuman GM-CSF antibody was added to the culture medium. The dose of rabbit antiserum was sufficient to neutralize the activity of lo4 U/mL of GM-CSF (data not shown).
NAC were resuspended in complete medium and placed on a nylon wool column at 37°C to remove remaining adherent cells and B cells. After 30 minutes, nylon woolpassed NAC were collected and subjected to a four-step discontinuous Percoll density gradient to separate LGL from mature T cells. The Percoll gradient was established with gradients varying by 2.5% from 42.5% to 50% Percoll, as described el~ewhere.~' LGL were collected from fractions 2 and 3 of the Percoll gradient and washed two times with PBS and cultured in complete medium at a concentration of 2 X lo6 cells/mL with 100 U/mL of IL-2 (provided by Hoffmann-La Roche, Nutley, NJ). The cells were activated for 3 to 4 days at 37°C in a 25-cmZ tissue culture flask.
A 5-hour 5'Cr-release assay was used to determine the ability of IL-2-cultured monocytes to be lysed by autologous LAK cells. Adherent monocytes were detached from the plastic surface by incubation with cold PBS for 10 minutes at 8°C. The recovered monocytes were labeled with 200 pCi of sodium [51Cr] chromate (Amersham Corp, Arlington Heights, IL) for 1 hour in 0.5 mL of medium with 5% human AB serum.32 Immediately after labeling of the target cells, the excess unincorporated "Cr was removed by washing twice with PBS and the cells were resuspended in complete medium at a concentration of 5 X lo4 cell/mL. The intracellular radioactivity was then determined by counting 0.1 mL of target cells by an automatic gamma counter (Wallac OY, Turku, Finland). The amount of radioactivity detected was taken as the maximum 5LCr incorporation. The LAK cells were added to labeled monocytes in a 96-well tissue culture plate (Costar) in triplicate wells for 5 hours at 37°C in a final volume of 0.2 mL per well. The effector:target ratio ranged from 20: 1 to 0.625: 1. After the indicated incubation period, 0.1 mL of supematant was collected from each well and experimental cpm was determined. Spontaneous release was determined by counting 0.1 mL of supernatant from non-LAK-treated monocytes after 5 hours of incubation in medium alone. The percentage of specific lysis was calculated by the formula:
Preparation of LAK cells.
Cytotoxicity assay.
Experimental cpm -Spontaneous cpm Maximal cpm Incorporated
The data are presented as lytic units (LU) per 1 X lo7 effector cells with 1 LU arbitrarily set as 20% lysis of labeled monocytes. GM-CSF release was detected from IL-2-treated monocytes using the human-derived acute megakaryocytic cell line, M07e.'~ Duplicates of a standard, rhGM-CSF, or monocyte supernatants were serially diluted in a 96-well tissue culture plate (Costar). Mo7e cells (5 X IO3 cells/well) were then added for 72 hours at 37°C in a final volume of 0.1 mL of Dulbecco's modified Eagle's medium (DMEM) with 5% heat-inactivated fetal calf serum (FCS; Hyclone, Logan, UT), 2 mmol/L L-glutamine, 100 U/mL of penicillin, and 100 pg/mL of streptomycin (GIBCO). Cell proliferation was detected by uptake of 'H-thymidine, which was added during the last 24 hours of incubation. The amount of GM-CSF was calculated from a standard curve using the Riacalc data management program (Wallac OY, Turku, Finland).
Fresh monocytes were obtained after plastic adherence and resuspended at a concentration of I X lo6 cells/0.2 mL in cold PBS with 0.02% azide and 2% FCS. The monocytes used in these experiments were not CD2 plus complement treated. After determining the degree of contamination by adherent LGL or T cells by fluorescence-activated cell sorter (FACS) analysis, the remaining experiments were performed using highly purified monocytes that were treated with CD2 plus complement. The cells were labeled with either fluorescein isothiocyanate (F1TC)-conjugated anti-IL-2Ra (CD25) or MikPl (anti-IL-
Biologic assay for GM-CSF.
Flow cytometric analysis o f f e s h monocytes.
For personal use only. on September 24, 2017. by guest www.bloodjournal.org From 2RP) MoAb and dually labeled with phycoerythrin (PE)-conjugated anti-CD14 (LeuMS), which is a specific monocyte marker. The monocytes were directly labeled with FITC-conjugated anti-IL-2Ra for 20 minutes at 4°C or indirectly labeled with MikPl anti-IL-ZRB for 20 minutes at 4"C, followed by washing and incubation with FlTC-conjugated goat antimouse Ig. The dual-labeled monocytes were analyzed by flow cytometric analysis (FACScan; Becton Dickinson). With the information that monocytes express IL-2R6, we examined whether IL-2 could modulate monocyte susceptibility to autologous LAK lysis. Initial experiments were performed using plastic-adherent monocytes incubated in complete medium with or without 100 U/mL of IL-2 for 4 days. In addition, a sample of the monocytes before culture with IL-2 was also treated with anti-CD2 plus complement to eliminate contaminating lymphocytes such as T and NK cells that could respond to IL-2. FACS analysis indicated that adherent monocytes could contain approximately 3% to 5% non-
RESULTS
Flow
IL-2 induction ofLAK susceptibility in monocytes.
CD14+ cells. Figure 2 shows that monocytes pretreated with anti-CD2 plus complement, when incubated with IL-2 for 4 days, acquired susceptibility to LAK lysis. On the other hand, unpunfied monocytes had little susceptibility to LAK lysis and appeared to be protected. We have shown in earlier experiments that as little as 10 U/mL of IFNy will protect monocytes from LAK lysis and will reverse the enhanced LAK lysis induced by treatment with GM-CSF.21 The protection Seen in unpunfied monocytes is probably due to IFNy released by contaminating NK cells responding to IL-2. Therefore, subsequent experiments have always included CD2 plus complement treatment of monocytes. The results in Table I show data obtained from lymphocyte-depleted monocytes of three donors in independent experiments and demonstrate the variability observed among donors as well as the relationship between the percentage of specific lysis and lytic units. The data obtained from cytotoxicity assays using "Cr release correlated well with trypan blue exclusion. Although the basal level of lysis varied from donor to donor, for each donor, IL-2 consistently activated monocytes to become highly susceptible to LAK lysis.
Kinetics of IL-2 induction of LAK susceptibility in monocytes.
After showing that IL-2-cultured monocytes are targets for LAK cell lysis after 4 days of incubation, we examined the kinetic response of monocytes to IL-2 in gaining susceptibility to LAK cells. Complete medium with or without 100 U/mL or 1,000 U/mL of rhIL-2 was added to anti-CD2 plus complement-treated monocytes on days 0 through 3. The two IL-2 dose levels examined were taken from two different For personal use only. on September 24, 2017. by guest www.bloodjournal.org From donors during two independent experiments. As shown in Fig 3, the maximum LAK cell lysis occurred against monocytes that were cultured in IL-2 for 4 days regardless of the dose of IL-2. Even after 2 days of exposure to IL-2, there was a statistical difference in lysis of IL-2-treated monocytes compared with that of mediumcultured control monocytes (P = .O33). In subsequent experiments, cytotoxicity assays were performed with monocytes cultured in IL-2 for 4 days to maximize LAK susceptibility.
Previous experiments have shown that IL-2 maximally activated monocyte tumoricidal function at a dose of 1.000 U/mL." Based on this information, we used doses ranging from 3 U/mL to 1.OOO U/mL to ascertain the dose of IL-2 responsible for maximal LAK cell lysis of human monocytes. Also. GM-CSF had previously been shown to induce maximum LAK recognition after culture of monocytes in 1.000 to 3,000 U/ Dose re.yponse ef monocj*tey to IL-2. mL for 4 days.35 Therefore, 1,000 U/mL ofGM-CSF (kindly provided by lmmunex Corp. Seattle, WA: specific activity. I X IO' U/mg of protein) was used in the experiment as a positive control to induce monocytic susceptibility (Fig 4) . A dosedependent response of monocytes to IL-2 was evident. At only 3 U/mL, IL-2 was capable of eliciting an enhanced response in monocytes to LAK cell lysis in comparison to the response of mediumcultured monocytes (1' = .008). Of significance was that 1.OOO U/mL of IL-2 had the same potency as that of 1.OOO U/mL ofGM-CSF, which represented the maximal inducibility in monocytes for LAK cell susceptibility."
GM-CSF rclease,fiom IL-2-cirltrrrcd moncxjm. k a u s e IL-2 and GM-CSF induced LAK susceptibility with similar kinetics, we investigated the possibility that IL-2 indirectly facilitated LAK susceptibility by inducing the release ofGM-CSF from monocytes. Therefore. supematants were collected from monocytes after culture with 100 or 1 .000 U/mL of IL-2 on days 2 through 4 of culture (Fig 5) or with various doscs of IL-2 for a fixed time of 4 days (Fig 6) . The supernatants were then tested for the presence of GM-CSF using a biologic assay. We found that cultured monocytes produced GM-CSF in association with both dosc and temporal exposure to IL-2. Incremental increases in the amount of GM-CSF were detected in the supernatants of monocytes with longer exposure to IL-2, which mimicked the LAK response of IL-2-treated monocytes with time (Fig 3) . The peak level of GM-CSF release was observed on day 4 of IL-2 exposure. with detectable GM-CSF seen at 3 U/mL of IL-2 and maximal induction at 1.000 U/mL of IL-2. Figure 6 shows that the induction of GM-CSF release from cultured monocytes was dose dependent. Because Mo7e cells proliferate in response to both GM-CSF and IL-3, neutrali7ation experiments were performed with anti-GM-CSF antibodies that showed that GM-CSF and not IL-3 was k i n g produced (data not shown).
GM-CW release and sriscc~tihilit,r to I-4 K 1j:vi.c. is mediated by IL-2RP. We next examined whether the mechanism of IL-2-enhanced lysis of monocytes was dependent or independent of GM-CSF release. It was possible that 1L-2 induced the release of GM-CSF from monocytes. which then acted to sensitize them to LAK lysis. If such was the case. anti-IL-2RB should inhibit both GM-CSF release and LAK susceg tibility of monocytes. Moreover. anti-GM-CSF should block IL-2-induced LAK susceptibility in monocytes as well. Therefore. monocytes were incubated with or without 300 For
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U/mL of IL-2 in the absence or presence of anti-li-2Rfl (Mikfll) or anti-GM-CSF for 4 days at 37OC before the measurement of GM-CSF in the supernatants and susceptibility to LAK cell lysis. Both antibodies reduced the appearance of IL-?-induced GM-CSF protein in monocyte supernatants and significantly reduced monocyte susceptibility to LAK cells. In terms of LAK susceptibility. both M i k o l and anti-GM-CSF efficiently blocked IL-$ enhancement of monocyte lysis, resulting in levels of lysis similar to that in medium control monocytes (Fig 7A) . Control mousc ascites or rabbit serum had no effect on the monocyte response to IL-2. Mikol and anti-GM-CSF had no effect on medium-cultured monocytes (data not shown). Wc also assessed the influence of Mikfll on the induction ofGM-CSF from monocytes. MikSI abrogated IL-2-induced GM-CSF from monocytes such that the GM-CSF levels in IL-2-treated monocytes and untreated control monocytes remained the same (Fig 7R) . With anti-GM-CSF. almost all GM-CSF present in the supernatants of IL-2-treated monocytes was neutralized. Control antibodies did not interfere with GM-CSF release or detection. Therefore, IL-2 appeared to induce LAK susceptibility in monocytes via induction of GM-CSF. In the absence of GM-CSF release, there was little monocyte susceptibility to LAK lysis. Monocytes from two donors in two separate experiments were cultured in complete medium 0, IL-2 100 U/mL (?), or IL-2 1,000 U/ m L (3 for 2 to 4 days. Supematants were collected and analyzed in duplicate by a 'H-thymidine proliferation assay using Mo7e cells.
Bar height represents the mean units per milliliter f. SD of GM-CSF, which was obtained from one of three representative donors at 1,000 U/mL and one of four representative donors at 100 U/mL. 'Statistically significant differences between IL-2-and mediumcultured cells (P < .05) by an independent samples t-test. 
DISCUSSION
Major emphasis on the use of IL-2 in immunotherapy has been based on its ability to activate T and NK cells against tumor ~e l l s .~.~ However, clinical toxicities associated with this form of therapy have limited its widespread
The basis for some toxicity may lie with the interaction of IG2-activated lymphocytes with normal cells such as endothelial cells and monocytes. '7~18,20,21 Based on recent independent findings that monocytes express IL-2RP and that GM-CSF-differentiated monocytes become LAK targets, the purpose of the present study was to determine whether IL-2 could functionally activate monocytes as measured by GM-CSF induction and whether this induction led to recognition by autologous LAK cell^.^^^^^ We provide clear evidence that monocytes respond to IL-2 in two ways: (1) by gaining susceptibility to LAK lysis, and (2) by producing high levels of GM-CSF. The two activities of monocytes occur in parallel and show almost identical dose-and time-dependent responses to IL2. We observed that plastic-adherent monocytes must be eliminated of all CD2+ T and NK cells before IL-2 induction of monocyte susceptibility to LAK lysis could be obtained. Both LAK susceptibility and GM-CSF release were detectable in T/NK-depleted monocytes after treatment with 3 U/mL of I L 2 and were maximal at 1,000 U/mL. In terms of kinetics, LAK susceptibility and GM-CSF induction were both found to be maximal at day 4 of IL-2 culture of the monocytes.
The supposition that IL-2 induction of LAK susceptibility in monocytes occurs via an autocrine GM-CSF loop is supported by experiments using specific antisera against IL-2Rp and GM-CSF. Both anti-IL-2RP and anti-GM-CSF were able to abrogate IL-2-enhanced monocyte susceptibility to LAK lysis. The addition of anti-IL-2Rp or anti-GM-CSF to monocytes during 4 days of culture with IL-2 prevented monocytes from being lysed beyond the level seen in IL-2-untreated monocytes. More importantly, the presence of anti-IL-2RP in the culture medium during IL-2 treatment also prevented the production of GM-CSF from monocytes. It is important to note that all experiments were performed with CD2 plus complement-treated adherent monocytes to eliminate contaminating NK and T cells, which are known to produce GM-CSF in response to other stimulant^.^^-^^ These results indicate that monocytes can respond to IL-2 via surface IL-2RP by GM-CSF production, which in turn can sensitize monocytes for LAK lysis. The amount of locally produced GM-CSF after IL-2 stimulation is difficult to correlate with exogenously added rhGM-CSF. Therefore, the possibility of a GM-CSF-independent component to monocyte sensitization to LAK lysis cannot be completely eliminated.
IL-2 can also trigger other functions in monocytes. Others have shown that IL-2 can enhance microbicidal and tumoricidal activities as well as IL-6 and TNFa production and c- For personal use only. on September 24, 2017. by guest www.bloodjournal.org From lymphocytes. 26 The significance of LAK recognition of GM-CSF-differentiated monocytes is not understood. The positive side of the IL-2-induced release of GM-CSF from monocytes may be involved in the activation of monocyte function against microbes and tumor ~e l l s .~' -~~ It is now well known that GM-CSF can directly activate monocytes against both intracellular and extracellular bacteria as well as fungi. GM-CSF is also known to activate neutrophil function against various micr0bes.4~ In addition, GM-CSF can stimulate monocytes to kill tumor targets.46 On the negative side, the recognition of IL-2-directed GM-CSF-sensitized monocytes by LAIC cells could account for some of the side effects associated with IL-2 therapy. Further investigation is necessary to determine if this selective recognition of monocytes by LAK cells constitutes a means of downregulation of accessory cells in an immune response after its induction or represents a bystander effect during tumor cell lysis.
